Overview

A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Status:
Completed

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

Summary

This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.

Phase:

Phase 3

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Ranibizumab